Gregory Demopulos MD reports a stock award at Omeros
By AlphaYouPublished Form 4
Demopulos Gregory A MD
Reporting filer
Gregory Demopulos MD reports a stock award, not an open-market purchase or sale, in Omeros Corp. Form 4 filed Oct 30, 2026 lists 1 entry.
- Disclosed
- Oct 30, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Performance Stock Option (right to buy) (derivative) | Demopulos Gregory A MD | 2026-10-28 | A | Grant or award | 500000 | 0 | 500,000 | 2 days | Filed terms
|
Performance Stock Option (right to buy) (derivative)
- Owner
- Demopulos Gregory A MD
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 500000
- Price
- 0
- Following holdings
- 500,000
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Performance Stock Option (right to buy)
- conversion Or Exercise Price: 17.88
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- transaction Shares: 500000
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- id: F1
- expiration Date: 2031-10-28
- underlying Security Title: Common Stock
- underlying Security Shares: 500000
- shares Owned Following Transaction: 500000
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Demopulos Gregory A MD: Chairman, CEO & President, Director.
- F1: No portion of the option was vested, and no shares were issued, on the grant date. The shares subject to the option will vest and become exercisable in four equal tranches subject to both (i) achievement of stock-price hurdles of $25.00, $30.00, $35.00 and $40.00 per share, respectively, calculated based on the aggregate volume-weighted average price of the registrant's common stock over 30 consecutive trading days, taken as a single measurement period, at any point during the option's five-year term, and (ii) satisfaction of a continued-service condition under which 25% of the shares in each tranche will become eligible for vesting on the first anniversary of the grant date and the remainder will become eligible for vesting in equal monthly installments over the following 36 months. The stock-price hurdles represent appreciation of approximately 40%, 68%, 96% and 124%, respectively, above the grant-date closing price of $17.88 per share, which is also the option's exercise price.
Original sources
Prepared automatically from public filing data. Report a correction.